Amedisys Inc. Stock Upgraded (AMED)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

NEW YORK ( TheStreet) -- Amedisys (Nasdaq: AMED) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's net income has been quite unimpressive.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Highlights from the ratings report include:
  • Net operating cash flow has increased to $33.56 million or 44.96% when compared to the same quarter last year. In addition, AMEDISYS INC has also vastly surpassed the industry average cash flow growth rate of -28.07%.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Despite the fact that it has already risen in the past year, there is currently no conclusive evidence that warrants the purchase or sale of this stock.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Health Care Providers & Services industry and the overall market, AMEDISYS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Providers & Services industry. The net income has significantly decreased by 76.6% when compared to the same quarter one year ago, falling from $7.88 million to $1.84 million.

Amedisys, Inc., together with its subsidiaries, operates as a home health and hospice company. It operates in two segments, Home Health and Hospice. Amedisys has a market cap of $558.3 million and is part of the health care sector and health services industry. Shares are up 53.4% year to date as of the close of trading on Wednesday.

You can view the full Amedisys Ratings Report or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.

If you liked this article you might like

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone and KKR Are Buying

Republican Sweep Poised to Agitate ACA-Vulnerable Health Care Services Stocks

Blackstone, KKR Unveil Second-Quarter Stock Picks

Blackstone, KKR Stock Picks Show Distinctly Bullish Tone